Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by Aubreyon Nov 24, 2015 12:37am
157 Views
Post# 24318663

clinical trials

clinical trialsDr Kulkarhi , who is a bladder cancer research specialist UHN  "views the trials as easily achievable"
The AGM was very revealing. It looks like smooth sailing ahead. UHN is is eager to do the trials. The enrollment will be over subscribed. The trial is happening locally in Toronto..The medical tech is ready to be deployed, .and the endpoint of 1b is safety and tollerability...that's a clear path, a no brainer.The test is immediately revealing...in HD video...and the standart endpoints of 3, 6 mths... the process has a history of an immunity effect. 
   The process is robust so small sample sizes are acceptable. I think the first test will get the ball rolling, and the second test with stats will be revealing and decisive.  By that time there will be an extensive pipeline. This much is known.
   There is allways the pesky unknown which haunts us all.     Aubrey
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse